studies

HEPATOLOGY, VOLUME 62, NUMBER 1 (SUPPL) AASLD ABSTRACTS 485A
preventive liver care measures for IBD patients
Disclosures:
K. Gautham Reddy - Advisory Committees or Review Panels: AASLD Transplant
Hepatology Pilot Steering Committee, ACG Training Committee, Program Director’s
Caucus Steering Committee, Gilead, Inercept, Bristol-Myers Squibb; Grant/
Research Support: Intercept, Ocera, Merck, Lumena
Helen S. Te - Advisory Committees or Review Panels: BMS; Grant/Research
Support: Abbvie, Conatus, BMS
Nancy Reau - Advisory Committees or Review Panels: Jannsen, Merck, AbbVie,
Intercept, Salix, BMS, Jannsen; Grant/Research Support: Merck, Gilead, BMS,
AbbVie, Jannsen, BI
The following authors have nothing to disclose: John N. Gaetano, Andrew I.
Aronsohn
Disclosures:
Robert E. Smith - Speaking and Teaching: Gilead, Salix, Abbvie, Janssen
The following authors have nothing to disclose: Chuan L. Miao, Sara West, Korta
Yuasa, Michael Komar, Stacy Prall
553
Disparities in the Quality of Death and Resource Utilization
in End-Stage Liver Disease
John N. Gaetano, K. Gautham Reddy, Andrew I. Aronsohn, Helen
S. Te, Nancy Reau; Department of Medicine, University of Chicago
Hospitals, Chicago, IL
Background: Various studies have shown increased utilization
of life-sustaining measures as well as increased end-of-life costs
in minorities. It is unknown if this disparity exists in the end-of life
care among patients with end-stage liver disease. Methods: The
Nationwide Inpatient Sample from 2012 was used to capture
patients with cirrhosis and a manifestation of hepatic decompensation
(variceal bleeding, hepatorenal syndrome, ascites,
spontaneous bacterial peritonitis, or portosystemic encephalopathy),
above the age of 39, who died in the hospital. The
primary predictor variable was race, while the primary outcome
measure was the use of life sustaining measures (cardiopulmonary
resuscitation, mechanical ventilation, reintubation,
hemodialysis, total parenteral nutrition, tracheostomy, and use
of vasopressors). Patient and hospital demographic information
as well as patient comorbidities were controlled for in multivariate
analysis. Results: There were 6,600 patients with cirrhosis
of the liver, age 40 or greater, who died in the hospital. Of
these, 4,178 had at least one form of hepatic decompensation
and were then included in to our analysis. Comorbidity
indexes across race were not significantly different. On univariate
analysis, black and Hispanic race had significantly
more frequent use of life sustaining measures (69% and 65%,
respectively) compared to white race (58%, p